Chronic Myeloid Leukemia Challenge

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

CML Overview

CML Incidence and Prevalence

Frontline Therapy for Newly Diagnosed CML

TKI Use Patterns in Newly Diagnosed CML

Resistance Mutations in CML

Treatment Options by Kinase Domain Mutations

Summary

Ponatinib

Ponatinib as Salvage Therapy

Phase 2 Trial of Ponatinib in Ph-Positive Leukemia: The PACE Trial

Ponatinib Dosing and Toxicity Management

Bosutinib

Bosutinib

Bosutinib Dosing and Toxicity Management

Sequential TKI Therapy

Omacetaxine Mepesuccinate

Omacetaxine Mepesuccinate

Omacetaxine Dosing and Toxicity Management

Omacetaxine in CP CML After ≥2 Prior TKIs

Allogeneic HSCT

Allogeneic HSCT as Salvage Therapy

TKI Maintenance After Allogeneic HSCT

Clinical Trials

Phase 1 Trial of ABL001 in CML

Patient Support and Communication

Patient Counseling: Newly Diagnosed CP CML

Patient Counseling: Salvage Setting